Viewing Study NCT04938232

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:32 PM
Ignite Modification Date: 2026-01-01 @ 7:19 PM
Study NCT ID: NCT04938232
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-03
First Post: 2021-06-08
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Sponsor: Dana-Farber Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hodgkin Lymphoma View
None Relapsed Hodgkin's Disease, Adult View
None Refractory Hodgkin Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hodgkin lymphoma View
None Relapsed Hodgkin's Disease, Adult View
None Refractory Hodgkin Lymphoma View